Business
Braveheart Bio Raises $382M in IPO for a China-Licensed Heart Drug
The cardiac-myosin inhibitor developer priced one of the year’s larger biotech IPOs to fund BHB-1893, a would-be rival to Bristol Myers’ Camzyos for a serious heart-muscle disease.